High-throughput DNA hypermethylation profiling in different ovarian epithelial cancer subtypes using universal bead array

Oncology Reports

Volumn 24, Issue 4, 2010, Pages 917-925

  Yoon, Man Soo ^a   Suh, Dong Soo ^a   Choi, Kyung Un ^a   Sol, Mee Young ^a   Shin, Dong Hoon ^a   Park, Won Young ^a   Lee, Jung Hee ^a   Jeong, Seong Muk ^a   Kim, Woo Gyeong ^a   Shin, Na Ri ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

Hypermethylation; Ovarian cancer; Universal bead array

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CARCINOGENESIS; CELL TYPE; CONTROLLED STUDY; CPG ISLAND; DNA DETERMINATION; DNA FINGERPRINTING; DNA METHYLATION; EPIGENETICS; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; TISSUE TYPES;

ADULT; AGED; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA;

EID: 77957338957     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000937     Document Type: Article

References (38)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 55: 10-30, 2005.
2. Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, Bergman C, Ehya H, Eisenberg BL and Cairns P: Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma and peritoneal fluid from ovarian cancer patients. Cancer Res 64: 6476-6481, 2004.
3. Khouja MH, Baekelandt M, Nesland JM and Holm R: The clinical importance of ki-67, p16, p14 and p57 expression in patients with advanced ovarian carcinoma. Int J Gynecol Pathol 26: 418-425, 2007.
4. Esteller M, Corn PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229, 2001.
5. Al-Kuraya K, Narayanappa R, Siraj AK, Al-Dayel F, Ezzat A, El Solh H, Al-Jommah N, Sauter G and Simon R: High frequency and strong prognostic relevance of O6-methylguanine DNA methyltransferase silencing in diffuse large B-cell lymphomas from the middle east. Hum Pathol 37: 742-748, 2006.
6. Chu LC, Eberhart CG, Grossman SA and Herman JG: Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer 119: 2487-2491, 2006.
7. Gu J, Berman D, Lu C, Wistuba II, Roth JA, Frazier M, Spitz MR and Wu X: Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res 12: 7329-7338, 2006. (Pubitemid 46095405)
8. Yang HJ, Liu VW, Wang Y, Tsang PC and Ngan HY: Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 6: 212, 2006.
9. Wiley A, Katsaros D, Chen H, Rigault de la Longrais IA, Beeghly A, Puopolo M, Singal R, Zhang Y, Amoako A, Zelterman D and Yu H: Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 107: 299-308, 2006.
10. Katsaros D, Cho W, Singal R, Fracchioli S, Rigault de la Longrais IA, Arisio R, Massobrio M, Smith M, Zheng W, Glass J and Yu H: Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol Oncol 94: 685-692, 2004.
11. Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD, Gazdar AF and Schorge JO: Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 11: 5365-5369, 2005.
12. Rathi A, Virmani AK, Schorge JO, Elias KJ, Maruyama R, Minna JD, Mok SC, Girard L, Fishman DA and Gazdar AF: Methylation profiles of sporadic ovarian tumors and non-malignant ovaries from high-risk women. Clin Cancer Res 8: 3324-3331, 2002.
13. Strathdee G, Appleton K, Illand M, Millan DW, Sargent J, Paul J and Brown R: Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 158: 1121-1127, 2001.
14. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G and Brown R: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65: 8961-8967, 2005.
15. Huang YW, Jansen RA, Fabbri E, Potter D, Liyanarachchi S, Chan MW, Liu JC, Crijns AP, Brown R, Nephew KP, van der Zee AG, Cohn DE, Yan PS, Huang TH and Lin HJ: Identification of candidate epigenetic biomarkers for ovarian cancer detection. Oncol Rep 22: 853-861, 2009.
16. Santin AD, Zhan F, Cane' S, Bellone S, Palmieri M, Thomas M, Burnett A, Roman JJ, Cannon MJ, Shaughnessy J Jr and Pecorelli S: Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer 92: 1561-1573, 2005.
17. Wei SH, Chen CM, Strathdee G, Harnsomburana J, Shyu CR, Rahmatpanah F, Shi H, Ng SW, Yan PS, Nephew KP, Brown R and Huang TH: Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 8: 2246-2252, 2002.
18. Bibikova M, Lin Z, Zhou L, Chudin E, Garcia EW, Wu B, Doucet D, Thomas NJ, Wang Y, Vollmer E, Goldmann T, Seifart C, Jiang W, Barker DL, Chee MS, Floros J and Fan JB: High-throughput DNA methylation profiling using universal bead arrays. Genome Res 16: 383-393, 2006.
19. Wu Q, Lothe RA, Ahlquist T, Silins I, Tropé CG, Micci F, Nesland JM, Suo Z and Lind GE: DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1 and CRABP1 as novel targets. Mol Cancer 6: 45, 2007.
20. Fiegl H, Windbichler G, Mueller-Holzner E, Goebel G, Lechner M, Jacobs IJ and Widschwendter M: HOXA11 DNA methylation - a novel prognostic biomarker in ovarian cancer. Int J Cancer 123: 725-729, 2008.
21. Cheng P, Schmutte C, Cofer KF, Felix JC, Yu MC and Dubeau L: Alterations in DNA methylation are early, but not initial, events in ovarian tumorigenesis. Br J Cancer 75: 396-402, 1997.
22. Choi YL, Kang SY, Choi JS, Kim SH, Lee SJ, Bae DS and Ahn G: Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas. Virchows Arch 448: 331-336, 2006.
23. Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S, Basset P, Chambon P and Gespach C: Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer 64: 70-75, 1995.
24. Le Bail B, Faouzi S, Boussarie L, Guirouilh J, Blanc JF, Carles J, Bioulac-Sage P, Balabaud C, Rosenbaum J: Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. J Pathol 189: 46-52, 1999.
25. Yang E, Kang HJ, Koh KH, Rhee H, Kim NK and Kim H: Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int J Cancer 121: 567-575, 2007.
26. Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS and Mok SC: SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 159: 609-622, 2001.
27. Krop I, Parker MT, Bloushtain-Qimron N, Porter D, Gelman R, Sasaki H, Maurer M, Terry MB, Parsons R and Polyak K: HIN-1, an inhibitor of cell growth, invasion and AKT activation. Cancer Res 65: 9659-9669, 2005.
28. Shigematsu H, Suzuki M, Takahashi T, Miyajima K, Toyooka S, Shivapurkar N, Tomlinson GE, Mastrangelo D, Pass HI, Brambilla E, Sathyanarayana UG, Czerniak B, Fujisawa T, Shimizu N and Gazdar AF: Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies. Int J Cancer 113: 600-604, 2005.
29. Fukuda H, Takahashi J, Watanabe K, Hayashi H, Morizane A, Koyanagi M, Sasai Y and Hashimoto N: Fluorescence-activated cell sorting-based purification of embryonic stem cell-derived neural precursors averts tumor formation after transplantation. Stem Cells 24: 763-771, 2006.
30. Lai HC, Lin YW, Huang TH, Yan P, Huang RL, Wang HC, Liu J, Chan MW, Chu TY, Sun CA, Chang CC and Yu MH: Identification of novel DNA methylation markers in cervical cancer. Int J Cancer 123: 161-167, 2008.
31. Crawford JM and Barton RW: Thy-1 glycoprotein: structure, distribution and ontogeny. Lab Invest 54: 122-135, 1986.
32. Abeysinghe HR, Pollock SJ, Guckert NL, Veyberman Y, Keng P, Halterman M, Federoff HJ, Rosenblatt JP and Wang N: The role of the THY1 gene in human ovarian cancer suppression based on transfection studies. Cancer Genet Cytogenet 149: 1-10, 2004.
33. Lung HL, Bangarusamy DK, Xie D, Cheung AK, Cheng Y, Kumaran MK, Miller L, Liu ET, Guan XY, Sham JS, Fang Y, Li L, Wang N, Protopopov AI, Zabarovsky ER, Tsao SW, Stanbridge EJ and Lung ML: THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma. Oncogene 24: 6525-6532, 2005.
34. Habuchi T, Luscombe M, Elder PA and Knowles MA: Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Genomics 48: 277-288, 1998.
35. Gao S, Worm J, Guldberg P, Eiberg H, Krogdahl A, Sørensen JA, Liu CJ, Reibel J and Dabelsteen E: Loss of heterozygosity at 9q33 and hypermethylation of the DBCCR1 gene in oral squamous cell carcinoma. Br J Cancer 91: 760-764, 2004.
36. Izumi H, Inoue J, Yokoi S, Hosoda H, Shibata T, Sunamori M, Hirohashi S, Inazawa J and Imoto I: Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. Hum Mol Genet 14: 997-1007, 2005.
37. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH and Hannon GJ: Twist is a potential oncogene that inhibits apoptosis. Genes Dev 13: 2207-2217, 1999.
38. Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, Garrett E, Argani P and Sukumar S: Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 64: 4442-4452, 2004. (Pubitemid 38856915)